Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Elixir Pharmaceuticals
company
About
Elixir Pharmaceuticals develops and commercializes pharmaceuticals for the treatment of metabolic diseases.
- 11 - 50
Details
- Last Funding Type
- Debt Financing
- Last Funding Money Raised
- $15M
- Industries
- Biotechnology,Diabetes,Pharmaceutical
- Founded date
- Jan 1, 1999
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
$98.50M
Elixir Pharmaceuticals has raised a total of
$98.50M
in funding over 2 rounds. Their latest funding was raised on
May 19, 2009 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 19, 2009 | Series D | $12M | 1 | — | — | Detail |
| Nov 27, 2006 | Debt Financing | $15M | 1 | — | — | Detail |
| Nov 27, 2006 | Series C | $31M | 2 | — | — | Detail |
| Oct 13, 2003 | Series B | $40.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Elixir Pharmaceuticals is funded by 2 investors.
ARCH Venture Partners
and Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series D |
Hercules Capital
|
— | Debt Financing |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
